anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A penicillin salt or mixture of salts is stabilized against discolouration and deterioration by admixture with 0.5 to 5 per cent of at least one alkaline earth metal chloride, e.g. calcium chloride or magnesium chloride, preferably in the anhydrous form. The salts are preferably alkali metal, e.g. sodium or organic base salts of penicillin.  The stabilized salts are employed medicinally (see Group VI).ALSO:A solid penicillin salt composition stabilized against deterioration and discolouration comprises an intimate mixture of a penicillin salt or salts with 0.5 to 5 per cent of at least one alkaline earth metal chloride, e.g. calcium chloride and magnesium chloride, preferably in the anhydrous form.  The penicillin salt is preferably an alkali metal or organic base salt of penicillin. Optional ingredients are (a) other drug (including antibiotics); (b) inert diluent; (c) surface-active agent, e.g. "Tween" (Registered Trade Mark); (d) thickening agent, e.g. carboxymethylcellulose; or (e) anti-foaming agents such as silicones.  In the example, sodium penicillin is stabilized by admixture with calcium chloride.
BACKGROUND AND AIMS: HBV and HIV coinfection is a common occurrence globally, with significant morbidity and mortality. Both viruses lead to immune dysregulation including changes in natural killer (NK) cells, a key component of antiviral defense and a promising target for HBV cure strategies. Here we used high-throughput single-cell analysis to explore the immune cell landscape in people with HBV mono-infection and HIV/HBV coinfection, on antiviral therapy, with emphasis on identifying the distinctive characteristics of NK cell subsets that can be therapeutically harnessed.
APPROACH AND RESULTS: Our data show striking differences in the transcriptional programs of NK cells. HIV/HBV coinfection was characterized by an over-representation of adaptive, KLRC2 -expressing NK cells, including a higher abundance of a chemokine-enriched ( CCL3/CCL4 ) adaptive cluster. The NK cell remodeling in HIV/HBV coinfection was reflected in enriched activation pathways, including CD3ζ phosphorylation and ZAP-70 translocation that can mediate stronger antibody-dependent cellular cytotoxicity responses and a bias toward chemokine/cytokine signaling. By contrast, HBV mono-infection imposed a stronger cytotoxic profile on NK cells and a more prominent signature of "exhaustion" with higher circulating levels of HBsAg. Phenotypic alterations in the NK cell pool in coinfection were consistent with increased "adaptiveness" and better capacity for antibody-dependent cellular cytotoxicity compared to HBV mono-infection. Overall, an adaptive NK cell signature correlated inversely with circulating levels of HBsAg and HBV-RNA in our cohort.
CONCLUSIONS: This study provides new insights into the differential signature and functional profile of NK cells in HBV and HIV/HBV coinfection, highlighting pathways that can be manipulated to tailor NK cell-focused approaches to advance HBV cure strategies in different patient groups.
BACKGROUND: Gemcitabine plus nab-paclitaxel (GnP) therapy has been shown to improve the prognosis in patients with metastatic pancreatic cancer (PC); however, the efficacy and safety of GnP in PC patients with malignant ascites (MA) remains unknown.
METHODS: We retrospectively investigated PC patients with peritoneal dissemination who had received GnP as first-line chemotherapy at our institution between March 2015 and August 2021. The following patient data were reviewed: patient characteristics, overall survival (OS), progression-free survival (PFS), objective response rate (ORR), adverse events (AEs), and relative dose intensity (RDI). The severity of MA was categorized based on the CT findings as grade 1 (small), grade 2 (moderate), or grade 3 (massive).
RESULTS: A total of 189 patients were included; the study endpoints were compared between patients with each ascites grade and 41 patients without MA. The MA was classified as grade 1 in 85 patients, grade 2 in 41 patients, and grade 3 in 22 patients. In the patients with MA, the median OS, PFS and ORR were 11.2 months, 5.7 months and 24.3%, respectively. The OS and PFS decreased with increasing the severity of MA; in particular, patients with grade 2 and 3 showed a poorer prognosis. There were no differences in AEs, except for anorexia, or the RDI according to the severity of MA.
CONCLUSION: GnP showed moderate efficacy with manageable safety profile in PC patients with MA. However, PC patients with moderate to massive ascites still have a dismal prognosis, and further development of effective treatments is needed.
A shelf-stable device for transdermally administering an active  pharmaceutical  to  a patient.   The  device  includes  a  drug reservoir  that  contains  the  drug  formulation.   In  one  preferred embodiment of the present invention, the drug reservoir is sandwiched between an upper and a lower solvent barrier film that are made from a material such as a polyester that will not absorb the drug and/or skin  permeating  enhancing  solvent,  if any,  contained  within  the reservoir.   The  drug  reservoir  and  solvent  barrier  films  are encapsulated within a hermetically-sealed compartment that protects the drug formulation from common environmental factors such as water vapor, oxygen, and light which can adversely affect the stability and efficacy   of   the   drug   formulation.    The   hermetically-sealed compartment  also  prevents  the  drug  formulation  from  coming  into contact with and possibly dissolving the adhesive used to secure the device to the patient's  skin.   In  another particularly  preferred embodiment of the present invention, the device's drug reservoir is encapsulated within a hermetically-sealed compartment that is made from solvent/environment barrier films that serve the dual functions of preventing the device's components from absorbing the drug/solvent formulation  from  the  reservoir,  and  protecting  the  drug/solvent formulation from common environmental factors.
1,189,340. Antigen adjuvant compositions. AMERICAN CYANAMID CO. 13 Sept., 1967 No. 41833/67. Heading A5B. Adjuvant compositions comprise a water-inoil or a water-in-oil-in-water emulsion, the oil being a physiologically acceptable oil, at least 0.15% w/v of a hydrated salt of a physiologically acceptable divalent or polyvalent metal and a physiologically acceptable fatty acid having from 12 to 24 carbon atoms, and an antigenic material present in a sufficient amount for producing immunologically satisfactory anti body formation. The metal may be Al, Fe, Mg, Ce, Zn, La or Bi and the fatty acid may be palmitic, stearic, lauric, myristic, arachidic, behenic, lignoceric, ricinoleic, oleic, erucic or linoleic acid, the preferred salt being aluminium monostearate. The oil may be peanut, safflower, soy bean, cotton seed, corn, chaulmoogra, olive, sesame, coconut or light mineral oil. The composition may also comprise an emulsifying agent of the type which favours formation of oil-in-water emulsions e.g. polyoxyethylene sorbitan monooleate. The antigenic materials may be derived from viruses e.g. influenza and foot and mouth antigens; mickettsia; bacteria e.g. tetanus toxoid; polysaccharides e.g. pneumococci, tumours allergic materials e.g. pollens, dust, danders and extracts thereof such as rag weed, house dust, pollen and grass extracts; and poisons or venoms of bees, wasps, poisonous snakes, scorpions and Lactrodectus mactans.
Earlier Phase II/III clinical trials indicate APV is effective in retarding HIV progression in the body. Despite these data, however, the drug has yet to receive regulatory approval. At the same time, there is an urgent need to grant pre-approval access to specific groups of patients eager to benefit from the anti-HIV potential inherent in APV. This study examines the relative effects APV has in patients with prior treatment failure or intolerance to previous protease inhibitor therapy.

Patients are seen in the clinic at pre-entry, baseline (Day 1), and every 4 weeks thereafter. Data on current antiretroviral treatment, HIV-1 associated conditions and adverse events are collected at every scheduled visit. Laboratory values (i.e., hematology, serum chemistry, plasma HIV-1 viral load and CD4+ cell count) are collected and assessed at pre-entry and Weeks 12, 24, 36, and 48. Optimal therapeutic effectiveness dictates the combined use of 2 or more antiretroviral agents in patients failing current antiretroviral therapy. APV, therefore, must be initiated as a component of a treatment regimen that also includes at least one other antiretroviral drug that the patient has not previously received.
Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
Simultaneous Transcutaneous and End-tidal CO2 measurements. Eligible patients will be first invited to fill in the Nijmegen questionnaire. Then, in an hyperventilation test, transcutaneous Carbon Dioxide Pressure will be recorded simultaneously with the standard End-tidal Carbon Dioxide Pressure measurement.
Subjects diagnosed with NAFLD were randomized to fenofibrate, an oral medication, nightly for eight weeks. Subjects will be given a dose of 200mg/day.
Aging in place is now recognized as a goal of most older adults. While medically driven interventions such as home health care assist older adults to age in place, these occur not as true preventive measures but as reactions to losses in function or health. The search for preventive methods to mitigate decline and unwanted moves from home and community is important. One such method, Preventive Home Visits (PHVs), has been utilized in parts of Europe for approximately two decades. The PHV model is based on infrequent but regular visits to an older adult's home by a trained practitioner (typically an occupational therapist or nurse). The visit is designed to assess the older person's situation and provide information and advice to optimize function and well-being. Evidence about PHV efficacy is mixed but generally supportive, and there is a distinct need to create and examine a preventive non-medical intervention model in the USA. A successfully developed and implemented approach could enhance lives and save costs. We plan to implement an intervention informed by a framework based on a synthesis of the World Health Organization function and disability model and the Occupational Therapy Practice Framework. We aim to implement and evaluate this PHV intervention in Orange County, North Carolina to assess the feasibility and effects of preventive home visits with older adults. We will use an experimental, repeated measures design in which approximately 120 older (75+ years) community-dwelling adults who are at-risk for functional decline are randomly assigned to experimental and comparison groups. The experimental group will receive the PHV intervention four times across a 12 month period. The comparison group will receive a minimal intervention of two informational phone calls and printed materials about local services during the same period. An occupational therapist with the requisite training and experience in home-based evaluation and intervention will conduct the experimental intervention. We will independently administer a set of standardized scales to both groups immediately pre-intervention, and again at regular intervals after each intervention. These outcome measures will cover the primary dimensions on which we hypothesize PHVs will have a positive influence: functional ability, participation, self-efficacy, life satisfaction, and self-reported health. Secondary outcomes include hospitalization and institutionalization. Analyses will compare the differences in outcomes for the two groups as well as assess several dimensions of intervention feasibility. These data will be the basis for a subsequent, enhanced intervention and study.
A ROR1-targeting antibody or an antigen-binding fragment thereof, a preparation method therefor, and an application thereof. The ROR1-targeting antibody or the antigen-binding fragment thereof comprises VL and VH. Said VL comprises the following CDRs or mutants thereof: VL CDR1, VL CDR2, and VL CDR3 as shown in SEQ ID NO: 69, 78, 84, respectively. Said VH comprises the following CDRs or mutants thereof: VH CDR1, VH CDR2, and VH CDR3 as shown in SEQ ID NO: 12, 33, 53, respectively. The described antibody or the antigen-binding fragment thereof has excellent binding affinity to ROR1 and has virtually no cross-reactivity with ROR2. The KD value thereof is equivalent to that of antibodies in the referenced prior art. The antibody or the antigen-binding fragment thereof further has a significant endocytosis effect and has an ADCC effect in tumor cells.
FIELD: medicine, hormones, immunology. SUBSTANCE: human somatotropin is administrated to animal and cell-free substrate with antibodies raised to human somatotropin is obtained. This substrate is incubated with human albumin at equivalent ratio of antibodies to human albumin in substrate to human albumin by number of determinant groups for time 3-4 i binding reaction. Obtained precipitate is separated and discarded. Insoluble immune reactive form of human albumin is used and after precipitate separating a substrate is incubated with human albumin again. EFFECT: improved method of preparing, decreased content of antibodies to human albumin, decreased risk of anaphylactic reaction. 3 cl, 1 tbl
Sevoflurane was evaluated in renally impaired patients with baseline serum creatinine > 1.5 mg/dL. Fourteen patients who received sevoflurane were compared with 12 patients who received isoflurane. In another study, 21 patients who received sevoflurane were compared with 20 patients who received enflurane. Creatinine levels increased in 7% of patients who received sevoflurane, 8% of patients who received isoflurane, and 10% of patients who received enflurane. Because of the small number of patients with renal insufficiency (baseline serum creatinine greater than 1.5 mg/dL) studied, the safety of sevoflurane administration in this group has not yet been fully established. Therefore, sevoflurane should be used with caution in patients with renal insufficiency (see WARNINGS).
Patients undergoing surgical treatment of pertrochanteric femoral fracture by intramedullary fixation will be included in the study. Patients will be older than 65 years and will belong to class I to III anesthesia risk according to the ASA classification. All patients included in the study will sign informed consent. Patients with dementia, mental illness, psychoorganically altered patients, and patients with a contraindication to dexmedetomidine, propofol, midazolam or with a contraindication to spinal anesthesia will be excluded from the study. All patients included in the study will have their blood taken for laboratory analysis of red blood cells, leukocytes, CRP, PCT, ChE and IL-6. Analyzes will be performed before the procedure, on the 1st, 3rd and 5th postoperative day. All patients will be tested for Mini mental state exame (MMSE) score before surgery to rule out pre-existing cognitive impairment, and those patients who have an MMSE value \<17 prior to surgery will be excluded from the study. In premedication, patients will be randomized using three envelopes selected by the blind researcher for the contents of each envelope. According to envelope patients will be divided into three groups: dexmedetomidine group (DS), propofol group (PS) and midazolam group (MS). Neuroaxial spinal block with intrathecal administration of 12.5 - 15 mg 0.5% levobupivacaine in the intervertebral space L3 / L4 or L4 / L5 will be the technique of anesthesia. After spinal block, patients in the DS group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 mcg / kg / h, patients in the PS group will receive a continuous infusion of propofol at a dose of 25-75 mcg / kg / min, while patients in the MS group will receive 0.05-0.07 mg / kg bolus i.v. midazolam. The total dose administered and the duration of surgery will be recorded. The volume of intraoperatively administered crystalloids or blood products will be recorded in all patients included in the study. In the postoperative period, pain will be measured with a numerical rating scale (NRS) 4, 8, 12 and 24 hours after surgery. All patients will receive the usual postoperative analgesia with metamizole and tramadol according to the protocol of the Department. On the 1st, 3rd and 5th postoperative days in the morning between 8.00 and 10.00, all patients will be tested for MMSE and Digit Symbol Substitution Test (DSST) score. A researcher who will evaluate MMSE and DSST values in the postoperative period will be blind to the drug that patients received intraoperatively.
Provided is a traditional Chinese medicine composition, a preparation method therefor and applications in treatment of insomnia. The composition comprises 3-6 g graminei rhizome, 3-6 g immature bitter orange, 2-4 g agilawood, 1-2 g cinnabar, 2-4 g amber, 3-6 g selfheal, 2-4 g polygala tenuifolia, and 1-5 ml edible vinegar. The preparation method comprises steps: the raw materials are prepared according to the above ratio, separately ground into powder, mixed evenly, divided into three parts, and made into round cakes with a diameter of 3 cm with 5 ml edible vinegar. When used, the prepared round cake with a diameter of 3 cm is coated with gauze to form an external application. The application is applied on the navel and replaced daily. The composition can treat intractable insomnia caused by variety of reasons with seven days as a course. Based on the clinical characters of insomnia and according to the traditional Chinese medicine meridian and viscera theories, medicines which can eliminate phlegm, dredge collaterals and calm nerves are screened out, form a composition according to a certain ratio, and provide a traditional Chinese medicine external prescription which can treat variety intractable insomnia.
Kumite is a karate sparring competition in which two players face off and perform offensive and defensive techniques. Depending on the players, there may be preliminary actions (hereinafter referred to as "pre-actions"), such as pulling the arms or legs, lowering the shoulders, etc., just before a technique is performed. Since the presence of a pre-action allows the opponent to know the timing of the technique, it is important to reduce pre-actions in order to improve the kumite. However, it is difficult for beginners and intermediate players to accurately identify their pre-actions and to improve them through practice. Therefore, this study aims to construct a practice support system that enables beginners and intermediate players to understand their pre-actions. In this paper, we focus on the forefist punch, one of kumite's punching techniques. We propose a method to estimate the presence or absence of a pre-action based on the similarity between the acceleration data of an arbitrary forefist punch and a previously prepared dataset consisting of acceleration data of the forefist punch without a pre-action. We found that the proposed method can estimate the presence or absence of a pre-action in an arbitrary forefist punch with an accuracy of 86%. We also developed KARATECH as a system to support the practice of reducing pre-actions using the proposed method. KARATECH shows the presence or absence of pre-actions through videos and graphs. The evaluation results confirmed that the group using KARATECH had a lower pre-action rate.
Provided are enzyme-catalyzed methods, and related products and kits, for efficiently linking a molecule to a protein or peptide and conjugates generated therefrom. An enzyme often utilized has transamidase activity, such as a sortase or related enzyme. Provided also are products, processes and kits for purifying in one step a recombinant target protein or target peptide initially expressed as a fusion product. The fusion product includes a solid phase association region, a peptidase, a peptidase recognition sequence and a target protein or target peptide. The peptidase is capable of cleaving the fusion protein when the fusion is bound to a solid support that specifically binds the solid phase association region, whereby the target protein or target peptide is released from the solid support in a substantially purified form. The peptidase sometimes has hydrolase activity, such as a sortase or related enzyme for example.
Peptide-based therapies for a retinal disease, injury, or condition in a subject involve administering to the subject a pharmaceutical composition containing at least one peptide derived from a heat shock protein, including Hsp20 and ??-crystallin. The administered peptides may be acetylated and/or conjugated to a cell-penetrating peptide. Administration of the peptides may reduce or prevent the loss of at least one retinal cell type, including retinal ganglion cells and retinal endothelial cells. The loss of such cells causes retinal damage and loss of eyesight in patients afflicted with an ocular condition. The pharmaceutical compositions may be administered intravitreally using an administration device. A single injection may be therapeutically sufficient for treating various ocular conditions.
Participants received single oral dose of Deflox® 50 milligrams (mg) tablet in Treatment Period 1 followed by a single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between the Treatment Periods 1 and 2.
The patients assigned to this group performed the exercise program and also received a manual therapy treatment applied by a physiotherapist. Two sessions were held per week for 4 weeks (8 sessions). Treatment consisted of traction, mobilization, and friction massage of the muscles of mastication.
The artificial antigen-presenting cell according to the present invention is based on a DNA microparticle having a micro-flower structure, which has features of a wrinkled surface and a porous inner side. The artificial antigen-presenting cell according to the present invention has a broad surface area due to the surface of the dendrite, thereby furthermore expanding an area in contact with the microvillus of a T cell and allowing the microvillus of the T cell to be inserted into an internal pore of the artificial antigen-presenting cell. In addition, the broad surface area of the artificial antigen-presenting cell maximizes a mathematical capacity of an antibody and the internal fine porous structure enables various cytokines, ligands, and the like to be readily mounted thereon. Therefore, the artificial antigen-presenting cell according to the present invention effectively contains various immune cell regulating materials and appropriately regulates activation and differentiation of the immune cells according to a kind of the contained material, so that the artificial antigen-presenting cell can be used to regulate immune functionality as well as treat various diseases such as cancer, an autoimmune disease and the like. Further, the artificial antigen-presenting cell of the present invention has high biocompatibility, so that there is an advantage of in vivo application. Therefore, the artificial antigen-presenting cell is expected to be useful clinically.